KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Deferred Taxes (2021 - 2025)

Pacific Biosciences Of California has reported Deferred Taxes over the past 4 years, most recently at -$546000.0 for Q1 2025.

  • Quarterly results put Deferred Taxes at -$546000.0 for Q1 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$546000.0 (down 166.34% YoY), and the annual figure for FY2025 was -$546000.0, down 166.34%.
  • Deferred Taxes for Q1 2025 was -$546000.0 at Pacific Biosciences Of California, down from -$205000.0 in the prior quarter.
  • Over the last five years, Deferred Taxes for PACB hit a ceiling of $1.2 million in Q4 2021 and a floor of -$718000.0 in Q4 2023.
  • Median Deferred Taxes over the past 4 years was -$375500.0 (2024), compared with a mean of -$73500.0.
  • Peak annual rise in Deferred Taxes hit 71.45% in 2024, while the deepest fall reached 71.45% in 2024.
  • Pacific Biosciences Of California's Deferred Taxes stood at $1.2 million in 2021, then tumbled by 161.11% to -$718000.0 in 2023, then soared by 71.45% to -$205000.0 in 2024, then tumbled by 166.34% to -$546000.0 in 2025.
  • The last three reported values for Deferred Taxes were -$546000.0 (Q1 2025), -$205000.0 (Q4 2024), and -$718000.0 (Q4 2023) per Business Quant data.